Unruptured aneurysms.

David O Wiebers; David G Piepgras; Robert D Brown; Irene Meissner; James Torner; Neal F Kassell; Jack P Whisnant; John Huston; Douglas A Nichols

doi:10.3171/jns.2002.96.1.0050

PubMed · 11795254

Unruptured aneurysms.

David O Wiebers·David G Piepgras·Robert D Brown·Irene Meissner·James Torner·Neal F Kassell·Jack P Whisnant·John Huston·Douglas A Nichols

View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Aneurysm, Ruptured Follow-Up Studies Humans Intracranial Aneurysm Risk Factors Smoking Subarachnoid Hemorrhage Comment Editorial

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

David O Wiebers, David G Piepgras, Robert D Brown, Irene Meissner, James Torner, Neal F Kassell, Jack P Whisnant, John Huston, Douglas A Nichols. 2002. Unruptured aneurysms.. https://doi.org/10.3171/jns.2002.96.1.0050

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Treatment of arteriovenous malformations of the brain.

The treatment of ruptured and unruptured brain arteriovenous malformations (AVMs) is driven by the need to prevent incident or recurrent intracranial hemorrhages. Improving feasibility of the rapidly developing endovascular, neurosurgical, and radiotherapeutic procedures leads to invasive treatment of an increasing number of neurologically intact patients with accidentally diagnosed AVMs. Recent data confirm that the natural history risk of unruptured AVMs is significantly lower than the risk of those presenting with rupture, and the treatment risk of invasive management of unruptured AVMs seems higher than their natural history risk. The treatment decision algorithm for these patients remains unsettled, as no randomized clinical trial data exist on the benefit of invasive AVM treatment for patients with bled or with unbled AVMs. The recently launched study A Randomized Trial of Unruptured Brain AVMs (ARUBA) will be the first trial randomizing patients with nonhemorrhaged AVMs to invasive versus conservative management.

Aneurysm, Ruptured↗

PubMed2007

[Less invasive cistemal approach and removal of subarachnoid hematoma for the treatment of ruptured cerebral aneurysms].

The risk of pial or brain injury while dissecting the cerebral cistern to treat acute subarachnoid hemorrhage might be higher than that of unruptured aneurysms, because visualizing the arachnoid trabeculae between the pia mater and the vessels can be complicated by thick subarachnoid clots filling the cerebral cistern. The author describes technical points of dissecting the cerebral cistern and the removal of subarachnoid hematomas during acute surgical treatment for subarachnoid hemorrhage. Tough arachnoid trabeculae form a "perivascular cistern" around the relatively major vessels in both the sylvian and interhemispheric fissures. The cistern can be separated without pial injury by identifying the microstructure surrounding the major vessels in the cistern and then cutting the arachnoid trabeculae. After bloodless dissection of the cistern, the subarachnoid hematoma can easily be irrigated and removed. The subarachnoid clot must be repeatedly irrigated by flushing the micro-space between arachnoid trabeculae with jets of water to ensure efficient removal. When the arachnoid trabeculae become transparent, small vessels and the arachnoid trabeculae can be differentiated as well as whether or not they can be cut. To treat sylvian hematoma, subpial hematomas extending from the insular cistern and intra-cisternal clots must be removed. Furthermore, inducing complete hemostasis by coagulating the subpial vessels is indispensable to prevent postoperative rebleeding.

Aneurysm, Ruptured↗

PubMed2006

Cerebral aneurysms.

Explore the source record for details and available documents.

Aneurysm, Ruptured↗